Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 18;8(10):e021488.
doi: 10.1136/bmjopen-2018-021488.

Prevention of early ventilation-acquired pneumonia (VAP) in comatose brain-injured patients by a single dose of ceftriaxone: PROPHY-VAP study protocol, a multicentre, randomised, double-blind, placebo-controlled trial

Claire Dahyot-Fizelier  1   2 , Denis Frasca  1   3 , Sigismond Lasocki  4 , Karim Asehnoune  5 , Dorothée Balayn  1 , Anne-Laure Guerin  1 , Pierre-François Perrigault  6 , Thomas Geeraerts  7 , Philippe Seguin  8 , Bertrand Rozec  5 , Djilali Elaroussi  9 , Vincent Cottenceau  10 , Clément Guyonnaud  1 , Olivier Mimoz  2   11 ; PROPHY-VAP Study group, ATLANREA group
Collaborators, Affiliations

Prevention of early ventilation-acquired pneumonia (VAP) in comatose brain-injured patients by a single dose of ceftriaxone: PROPHY-VAP study protocol, a multicentre, randomised, double-blind, placebo-controlled trial

Claire Dahyot-Fizelier et al. BMJ Open. .

Abstract

Introduction: Ventilator-associated pneumonia (VAP) is the first cause of healthcare-associated infections in intensive care units (ICUs) and brain injury is one of the main risk factors for early-onset VAP. Antibiotic prophylaxis has been reported to decrease their occurrence in brain-injured patients, but a lack of controlled randomised trials and the risk of induction of bacterial resistance explain the low level of recommendations. The goal of this study is to determine whether a single dose of ceftriaxone within the 12 hours postintubation after severe brain injury can decrease the risk of early-onset VAP.

Methods and analysis: The PROPHY-VAP is a French multicentre, randomised, double-blind, placebo-controlled, clinical trial. Adult brain-injured patients (n=320) with a Glasgow Coma Scale ≤12, requiring mechanical ventilation for more than 48 hours, are randomised to receive either a single dose of ceftriaxone 2 g or a placebo within the 12 hours after tracheal intubation. The primary endpoint is the proportion of patients developing VAP from the 2nd to the 7th day after mechanical ventilation. Secondary endpoints include the proportion of patients developing late VAP (>7 days after tracheal intubation), the number of ventilator-free days, VAP-free days and antibiotic-free days, length of stay in the ICU, proportion of patients with ventilator-associated events and mortality during their ICU stay.

Ethics and dissemination: The initial research project was approved by the Institutional Review Board of OUEST III (France) on 20 October 2014 (registration No 2014-001668-36) and carried out according to the principles of the Declaration of Helsinki and the Clinical Trials Directive 2001/20/EC of the European Parliament relating to the Good Clinical Practice guidelines. The results of this study will be presented in national and international meetings and published in an international peer-reviewed journal.

Trial registration number: NCT02265406; Pre-results.

Keywords: brain-injured patient; ceftriaxone; prophylaxis; ventilator-associated pneumonia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Rello J, Ausina V, Ricart M, et al. . Nosocomial pneumonia in critically ill comatose patients: need for a differential therapeutic approach. Eur Respir J 1992;5:1249–53. - PubMed
    1. Vallés J, Peredo R, Burgueño MJ, et al. . Efficacy of single-dose antibiotic against early-onset pneumonia in comatose patients who are ventilated. Chest 2013;143:1219–25. 10.1378/chest.12-1361 - DOI - PubMed
    1. Roquilly A, Mahe PJ, Seguin P, et al. . Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. JAMA 2011;305:1201–9. 10.1001/jama.2011.360 - DOI - PubMed
    1. Cavalcanti M, Ferrer M, Ferrer R, et al. . Risk and prognostic factors of ventilator-associated pneumonia in trauma patients. Crit Care Med 2006;34:1067–72. 10.1097/01.CCM.0000206471.44161.A0 - DOI - PubMed
    1. Kalil AC, Metersky ML, Klompas M, et al. . Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society. Clin Infect Dis 2016;63:e61–111. 10.1093/cid/ciw353 - DOI - PMC - PubMed

Publication types

Associated data